A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
Latest Information Update: 31 Jul 2025
At a glance
- Drugs LTP 001 (Primary)
- Indications Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Jul 2025 Planned End Date changed from 3 Sep 2026 to 31 Dec 2028.
- 16 Jul 2025 Planned primary completion date changed from 6 Aug 2026 to 29 Nov 2028.
- 15 Nov 2024 Status changed from not yet recruiting to recruiting.